| 1.29 -0.015 (-1.15%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.67 | 1-year : | 1.95 |
| Resists | First : | 1.42 | Second : | 1.67 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.19 | Second : | 1.04 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 1.3 |
| MA(100) : | 1.44 |
MA(250) : | 2.37 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 53.7 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 6.75 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BBLG ] has closed above bottom band by 31.0%. Bollinger Bands are 50.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.27 - 1.28 | 1.28 - 1.29 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Thu, 23 Apr 2026
Bone Biologics To Carry Out 1-for-6 Reverse Stock Split On June 10th, 2025 - 富途牛牛
Tue, 23 Dec 2025
BBLG Stocks on the Verge: How Will They Perform? - StocksToTrade
Tue, 23 Dec 2025
Bone-healing treatment in development now lasts 2 years on the shelf in tests - Stock Titan
Thu, 04 Sep 2025
Bone Biologics expects to complete enrollment in NB1 clinical trial - Investing.com
Thu, 04 Sep 2025
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook - Yahoo Finance
Fri, 27 Jun 2025
Bone Biologics Announces Pricing of $5.0 Million Public Offering - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -2.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.9 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.49 |
| PEG Ratio | 0 |
| Price to Book value | 0.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|